The post-market review of the ODTP identified stigma, discrimination and cost as barriers to access, with patients borrowing money, eating less, and ultimately going without treatment. …
Post-market review identified cost and stigma as barriers to treatment
May 11, 2023 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The industry walked out on Britain, and what it cost to win them back
October 22, 2026 - - Latest News -
BioNTech opens mRNA plant, putting Melbourne's north on the biotech map
October 22, 2026 - - Latest News -
An architect of the first industry–Commonwealth medicines pact to lead CSL
October 21, 2026 - - Latest News -
Quarterly update shows Telix holds course for a US$1 billion milestone year
October 21, 2026 - - Latest News -
Chemist Warehouse keeps growing as Sigma sets its sights on oral GLP-1s
October 21, 2026 - - Latest News -
America's ever rising GLP-1 curve and how Australia is following
October 21, 2026 - - Latest News -
Patient groups across Asia-Pacific push for a say on medicine prices
October 21, 2026 - - Latest News